Biogen (BIIB) Q4 2024 Earnings Call Transcript

Biogen reported Q4 revenue of $2.5 billion, up 3% year over year, with full-year revenue down 2% to $9.7 billion but non-GAAP EPS rising 12% to $16.47 and free cash flow improving to $2.7 billion. The company guided 2025 revenue to a mid-single-digit decline and EPS to $15.25-$16.25, reflecting MS franchise pressure, a roughly 1% FX headwind, and a $50 million-$100 million Medicare Part D impact, partially offset by growth in LEQEMBI, SKYCLARYS, and ZURZUVAE. Management also highlighted continued pipeline prioritization, cost savings from Fit for Growth, and upcoming LEQEMBI catalysts including subcutaneous dosing and blood-based diagnostics.

Analysis

Biogen is transitioning from an MS-vintage cash cow into a three-engine story: launch portfolio, cost reset, and pipeline optionality. The key second-order change is not just that new products are offsetting MS decay, but that operating leverage is reappearing while management is deliberately compressing the R&D base, which raises the probability of multiple expansion if launch execution keeps compounding. The market may still be anchoring on “ex-MS decline,” but the business is increasingly a cash-generative platform with a visible set of catalysts over the next 6-18 months.

The real swing factor is LEQEMBI, where the growth rate is likely constrained less by efficacy and more by diagnosis, capacity, and prescriber expansion. Blood-based diagnostics and subcutaneous dosing are not just convenience upgrades; they attack the bottleneck that keeps a large fraction of eligible patients from ever entering the funnel. If adoption broadens, the revenue curve can inflect faster than consensus expects, and that would matter disproportionately because each incremental billion in sales has outsized impact on earnings and valuation.

The contrarian view is that the Street may be underpricing the durability of the cash engine while overestimating the speed of launch friction resolution. In the near term, MS erosion and Part D redesign still create noise, so the next 1-2 quarters likely won’t be clean. But over 12-24 months, the combination of cost savings, launch maturation, and a few binary pipeline readouts makes this more of a self-help and execution story than a balance-sheet-constrained turnaround.

Key Decisions for Investors

• Initiate a tactical long in BIIB over the next 1-3 months ahead of LEQEMBI maintenance/subcutaneous catalysts and 2025 operating leverage; risk/reward favors upside if launch friction eases faster than expected.
• Pair trade: long BIIB / short NVO for 6-12 months. Biogen has a clearer near-term catalyst stack and cost discipline, while Novo’s Alzheimer’s optionality is still largely event-driven and less de-risked.
• Use call spreads in BIIB rather than outright equity for the next 6-9 months to express upside from LEQEMBI acceleration and Fit for Growth savings while limiting exposure to MS erosion and FX headwinds.
• Buy RPRX on weakness as a second-order beneficiary of structured financing / royalty monetization appetite if Biogen’s deal model proves repeatable; this is a lower-beta way to express the capital-efficiency theme.
• Avoid chasing the move immediately after strong launch prints; the better entry is on any pullback tied to quarterly MS noise, since the setup is a 12-18 month compounding story rather than a clean one-quarter beat.